Meredith L Kilgore1, Dana P Goldman. 1. University of Alabama at Birmingham, School of Public Health, 1665 University Blvd. RPHB 330, Birmingham, AL 35294-0022, USA. mkilgore@uab.edu
Abstract
OBJECTIVE: To estimate the effect of clinical trial participation on drug utilization, drug costs, and out-of-pocket expenditures for cancer patients. METHODS: The study used a national probability sample of patients participating in cancer clinical trials and a matched cohort of patients not enrolled in trials but receiving treatment for the same cancers from the same providers. Subjects were interviewed about prescription drug utilization and out-of-pocket drug expenditures. We estimated treatment costs based on a large pharmacy transaction database. Multivariate regression was used to estimate the effects of trial participation on drug costs and out-of-pocket expenditures. RESULTS: Participants in clinical trials incurred higher prescription drug costs than non-participants: an average of $131 over a six-month period. However, there was no significant difference in out-of-pocket expenditures for the two groups. CONCLUSIONS: Participation in clinical trials was associated with a modest increase in prescription drug utilization and costs, but these costs did not necessarily impose an economic burden on cancer trial participants.
OBJECTIVE: To estimate the effect of clinical trial participation on drug utilization, drug costs, and out-of-pocket expenditures for cancerpatients. METHODS: The study used a national probability sample of patients participating in cancer clinical trials and a matched cohort of patients not enrolled in trials but receiving treatment for the same cancers from the same providers. Subjects were interviewed about prescription drug utilization and out-of-pocket drug expenditures. We estimated treatment costs based on a large pharmacy transaction database. Multivariate regression was used to estimate the effects of trial participation on drug costs and out-of-pocket expenditures. RESULTS:Participants in clinical trials incurred higher prescription drug costs than non-participants: an average of $131 over a six-month period. However, there was no significant difference in out-of-pocket expenditures for the two groups. CONCLUSIONS: Participation in clinical trials was associated with a modest increase in prescription drug utilization and costs, but these costs did not necessarily impose an economic burden on cancer trial participants.
Authors: Joseph M Unger; Dawn L Hershman; Kathy S Albain; Carol M Moinpour; Judith A Petersen; Kenda Burg; John J Crowley Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Cheryl K Altice; Matthew P Banegas; Reginald D Tucker-Seeley; K Robin Yabroff Journal: J Natl Cancer Inst Date: 2016-10-20 Impact factor: 13.506